Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL8326 in Advanced Solid Tumors
NCT04890587Phase 1Unknown
- Sponsor
- Advenchen Laboratories
- Start
- Aug 2017
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AL8326 in solid tumor (advanced stage), sponsored by Advenchen Laboratories. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Status: unknown.
02
Drugs
AL8326
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04890587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890587.